Prevention of Heart Failure in Hypertension—Disentangling the Role of Evolving Left Ventricular Hypertrophy and Blood Pressure Lowering: The ALLHAT Study

por Johnson, Kyle, Oparil, Suzanne, Davis, Barry R., Tereshchenko, Larisa G.
Publicado 2019

The 18-year risk of cancer, angioedema, insomnia, depression, and erectile dysfunction in association with antihypertensive drugs: post-trial analyses from ALLHAT–Medicare linked d...

por Du, Xianglin L., Martinez, Journey, Yamal, Jose-Miguel, Simpson, Lara M., Davis, Barry R.
Publicado 2023

Effects of Posttrial Antihypertensive Drugs on Morbidity and Mortality: Findings from 15-Year Passive Follow-Up after ALLHAT Ended

por Du, Xianglin L., Simpson, Lara M., Tandy, Brian C., Bettencourt, Judy, Davis, Barry R.
Publicado 2021

Risk of hospitalized and non-hospitalized gastrointestinal bleeding in ALLHAT trial participants receiving diuretic, ACE-inhibitor, or calcium-channel blocker

por Du, Xianglin L., Simpson, Lara M., Tandy, Brian C., Bettencourt, Judith L., Davis, Barry R.
Publicado 2021

Risk of Developing Alzheimer’s Disease and Related Dementias in ALLHAT Trial Participants Receiving Diuretic, ACE-Inhibitor, or Calcium-Channel Blocker with 18 Years of Follow-Up

por Du, Xianglin L., Simpson, Lara M., Osani, Mikala C., Yama, Jose-Miguel, Davis, Barry R.
Publicado 2022

Mortality and Morbidity Among Individuals With Hypertension Receiving a Diuretic, ACE Inhibitor, or Calcium Channel Blocker: A Secondary Analysis of a Randomized Clinical Trial

por Yamal, Jose-Miguel, Martinez, Journey, Osani, Mikala C., Du, Xianglin L., Simpson, Lara M., Davis, Barry R.
Publicado 2023

Disparities in Socioeconomic Context and Association With Blood Pressure Control and Cardiovascular Outcomes in ALLHAT

por Shahu, Andi, Herrin, Jeph, Dhruva, Sanket S., Desai, Nihar R., Davis, Barry R., Krumholz, Harlan M., Spatz, Erica S.
Publicado 2019

Genetic and Adverse Health Outcome Associations with Treatment Resistant Hypertension in GenHAT

por Lynch, Amy I., Irvin, Marguerite R., Davis, Barry R., Ford, Charles E., Eckfeldt, John H., Arnett, Donna K.
Publicado 2013

Investigating the stratified efficacy and safety of pharmacological blood pressure-lowering: an overall protocol for individual patient-level data meta-analyses of over 300 000 ran...

por Rahimi, Kazem, Canoy, Dexter, Nazarzadeh, Milad, Salimi-Khorshidi, Gholamreza, Woodward, Mark, Teo, Koon, Davis, Barry R, Chalmers, John, Pepine, Carl J
Publicado 2019

Pharmacogenetic Association of NOS3 Variants with Cardiovascular Disease in Patients with Hypertension: The GenHAT Study

por Zhang, Xue, Lynch, Amy I., Davis, Barry R., Ford, Charles E., Boerwinkle, Eric, Eckfeldt, John H., Leiendecker-Foster, Catherine, Arnett, Donna K.
Publicado 2012

Pharmacogenetic Associations of MMP9 and MMP12 Variants with Cardiovascular Disease in Patients with Hypertension

por Tanner, Rikki M., Lynch, Amy I., Brophy, Victoria H., Eckfeldt, John H., Davis, Barry R., Ford, Charles E., Boerwinkle, Eric, Arnett, Donna K.
Publicado 2011

Do Bayesian adaptive trials offer advantages for comparative effectiveness research? Protocol for the RE-ADAPT study

por Connor, Jason T, Luce, Bryan R, Broglio, Kristine R, Ishak, K Jack, Mullins, C Daniel, Vanness, David J, Fleurence, Rachael, Saunders, Elijah, Davis, Barry R
Publicado 2013

RYR3 gene polymorphisms and cardiovascular disease outcomes in the context of antihypertensive treatment

por Lynch, Amy I, Irvin, Marguerite R, Boerwinkle, Eric, Davis, Barry R, Vaughan, Laura K, Ford, Charles E., Aissani, Brahim, Eckfeldt, John H, Arnett, Donna K, Shrestha, Sadeep
Publicado 2012

Clinical and demographic correlates of medication and visit adherence in a large randomized controlled trial

por Whittle, Jeff, Yamal, José-Miguel, Williamson, Jeffrey D., Ford, Charles E., Probstfield, Jeffrey L., Beard, Barbara L., Marginean, Horia, Hamilton, Bruce P., Suhan, Pamela S., Davis, Barry R.
Publicado 2016

Antihypertensive drug effects on long-term blood pressure: an individual-level data meta-analysis of randomised clinical trials

por Canoy, Dexter, Copland, Emma, Nazarzadeh, Milad, Ramakrishnan, Rema, Pinho-Gomes, Ana-Catarina, Salam, Abdul, Dwyer, Jamie P, Farzadfar, Farshad, Sundström, Johan, Woodward, Mark, Davis, Barry R, Rahimi, Kazem
Publicado 2022

Validation of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants Assigned to Doxazosin and Chlorthalidone

por Piller, Linda B, Davis, Barry R, Cutler, Jeffrey A, Cushman, William C, Wright, Jackson T, Williamson, Jeff D, Leenen, Frans HH, Einhorn, Paula T, Randall, Otelio S, Golden, John S, Haywood, L Julian
Publicado 2002

The effects of genes implicated in cardiovascular disease on blood-pressure response to treatment among treatment-naïve hypertensive African Americans in the GenHAT study

por Do, Anh N, Lynch, Amy I, Claas, Steven A, Boerwinkle, Eric, Davis, Barry R, Ford, Charles E, Eckfeldt, John H, Tiwari, Hemant K, Arnett, Donna K, Irvin, Marguerite R
Publicado 2016

Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis

por Copland, Emma, Canoy, Dexter, Nazarzadeh, Milad, Bidel, Zeinab, Ramakrishnan, Rema, Woodward, Mark, Chalmers, John, Teo, Koon K, Pepine, Carl J, Davis, Barry R, Kjeldsen, Sverre, Sundström, Johan, Rahimi, Kazem
Publicado 2021

Pravastatin and cardiovascular outcomes stratified by baseline eGFR in the lipid-lowering component of ALLHAT

por Rahman, Mahboob, Baimbridge, Charles, Davis, Barry R., Barzilay, Joshua I., Basile, Jan N., Henriquez, Mario A., Huml, Anne, Kopyt, Nelson, Louis, Gail T., Pressel, Sara L., Rosendorff, Clive, Sastrasinh, Sithiporn, Stanford, Carol
Publicado 2013

The effects of angiotensinogen gene polymorphisms on cardiovascular disease outcomes during antihypertensive treatment in the GenHAT study

por Do, Anh N., Irvin, Marguerite R., Lynch, Amy I., Claas, Steven A., Boerwinkle, Eric, Davis, Barry R., Ford, Charles E., Eckfeldt, John H., Tiwari, Hemant K., Limdi, Nita A., Arnett, Donna K.
Publicado 2014